214 related articles for article (PubMed ID: 25973979)
1. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.
Wong GL; Tse YK; Wong VW; Yip TC; Tsoi KK; Chan HL
Hepatology; 2015 Sep; 62(3):684-93. PubMed ID: 25973979
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.
Wong GL; Tse YK; Yip TC; Chan HL; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2017 May; 45(9):1213-1224. PubMed ID: 28239880
[TBL] [Abstract][Full Text] [Related]
3. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma.
Wong GL; Tse YK; Chan HL; Yip TC; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2016 Apr; 43(7):802-13. PubMed ID: 26843444
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
5. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B.
Wong GL; Seto WK; Wong VW; Yuen MF; Chan HL
Aliment Pharmacol Ther; 2018 Mar; 47(6):730-737. PubMed ID: 29359487
[TBL] [Abstract][Full Text] [Related]
6. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.
Qi X; Wang JY; Mao RC; Zhang JM
J Viral Hepat; 2015 Jan; 22(1):46-54. PubMed ID: 25402626
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
Suárez E; Buti M; Rodríguez M; Prieto M; Pascasio-Acevedo JM; Casanovas T; Crespo J; Tapiador JAR; Gómez-Rodríguez R; Figueruela B; Diago M; Morillas RM; Zozaya JM; Calleja JL; Casado M; Molina E; Fuentes J; Simón MA
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):267-271. PubMed ID: 30576297
[TBL] [Abstract][Full Text] [Related]
9. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
Papatheodoridis GV
Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
[TBL] [Abstract][Full Text] [Related]
10. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
11. Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study.
Yao J; Zhou L; Hua X; Kong M; Chen Y; Duan Z
Nutrition; 2016; 32(11-12):1206-10. PubMed ID: 27283043
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.
de Fraga RS; Van Vaisberg V; Mendes LCA; Carrilho FJ; Ono SK
J Gastroenterol; 2020 May; 55(5):496-514. PubMed ID: 32185517
[TBL] [Abstract][Full Text] [Related]
13. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
[TBL] [Abstract][Full Text] [Related]
14. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
15. Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
Carey I; Byrne R; Childs K; Horner M; Bruce M; Wang B; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Oct; 25(10):1139-1150. PubMed ID: 29660209
[TBL] [Abstract][Full Text] [Related]
16. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.
Lee TY; Hsu YC; Yu SH; Lin JT; Wu MS; Wu CY
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):947-954.e4. PubMed ID: 28951229
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection.
Coppola N; Stanzione M; Messina V; Pisaturo M; De Pascalis S; Macera M; Tonziello G; Fiore M; Sagnelli C; Pasquale G; Sagnelli E
J Viral Hepat; 2012 Dec; 19(12):890-6. PubMed ID: 23121368
[TBL] [Abstract][Full Text] [Related]
18. [Research advances in withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients].
Hu N; You H
Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):704-707. PubMed ID: 27788731
[TBL] [Abstract][Full Text] [Related]
19. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
[TBL] [Abstract][Full Text] [Related]
20. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
